Consequently, despite the active clinical use of RNR inhibitors for several decades, the mechanism of how this class of drugs, as both single agents and in combination therapies, induces toxicity in cancer cells is poorly understood (1, 4, 5, 9). Here, NR2E3 is linked to cancer.